Updated April 9, 2014, at 1 p.m. EST with comments from Intuitive Surgical.
Intuitive Surgical
Intuitive Surgical hopes to conquer more complex surgeries with new da Vinci Xi
Intuitive Surgical shares jump on FDA clearance for new da Vinci robot
Intuitive Surgical (NSDQ:ISRG) shares opened up 11% this morning, after the medical device company said the FDA cleared the latest version of its da Vinci surgical robot, and quickly surged past the $500 mark..
Judge cuts Biolase board of directors | Medtech legal news for the week of Mar. 31, 2014
Intuitive Surgical recalls da Vinci cannulae
UPDATED March 28, 2014, with details from Intuitive Surgical.
Intuitive Surgical (NSDQ:ISRG) said it’s recalling some of the cannulae used during procedures with its da Vinci robotic surgery system, saying they can become damaged if not installed properly by the user.
Medicare maintains reimbursement rate for Abiomed heart pump | Medtech Wall Street news for the week of Mar. 24, 2014
Shareholders sue Intuitive Surgical over adverse events, recalls
Intuitive Surgical (NSDQ:ISRG) is under fire from shareholders for allegedly under-reporting adverse events associated with its da Vinci surgical robot and concealing at least 3 recalls from the FDA.
Love at first tweet: A look at medtech’s 1st forays into the social network
First impressions can be daunting primarily because they can have a long-lasting influence on a relationship, but what does it mean to make a 1st impression online?
Some of medtech’s biggest companies have made themselves Twitter regulators, but each had to start somewhere. Here are some of the industry’s 1st tweets:
Ad endorsing da Vinci robot violated U of Illinois policies, review finds
by Charles Ornstein, ProPublica
An internal review by the University of Illinois has found that an advertisement in which a university surgical team endorsed a pricey surgical robot violated school policies.
TRC extends mini-tender offer for Intuitive Surgical
Shareholders of robotic surgical systems maker Intuitive Surgical (NSDQ:ISRG) have an extra 11 days to consider TRC Capital’s so-called "mini-tender" offer to purchase shares at $405 apiece.